Γεώργιος Δ. Κατσιμαγκλής. Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ

Transcription

1 Γεώργιος Δ. Κατσιμαγκλής Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ

2 I have no disclosures

3 ΣΥΧΝΟΤΗΤΑ An atrial septal defect (ASD) is a deficiency of the atrial septum. ASDs account for about 10-15% of all congenital cardiac anomalies Research indicates that the incidence of congenital heart disease (CHD) is 0.8% of the US population. Approximately 7% of these individuals, or about 1 in 1500 live births, have an ASD. An estimated 15-30% of healthy adults have an unfused foramen ovale in which the valve functions normally but has failed to fuse.

4 ΑΝΟΙΚΤΟ ΩΟΕΙΔΕΣ ΤΡΗΜΑ

5 ΔΟΜΗ-ΦΥΣΙΟΛΟΓΙΑ

6 Pathophysiology of PFO and Paradoxical Embolism

7 ΠΑΡΑΔΟΞΗ ΕΜΒΟΛΗ

8 ΠΑΡΑΔΟΞΗ ΕΜΒΟΛΗ

9 CLOSURE I(2010)

10 CLOSURE I(RESULTS)

11 PC TRIAL

12 PC TRIAL ENDPOINTS

13 PC TRIAL RESULTS

14 RESPECT TRIAL

15 RESPECT TRIAL RESULTS

16 RESULTS(2)

17 ΕΠΑΝΕΚΤΙΜΗΣΗ ΤΗΣ RESPECT

18 ΑΠΟΤΕΛΕΣΜΑΤΑ The mean follow-up for the PFO group was 5.5 years and 4.9 years for the medical management group [total patient years: 2,769 (PFO) and 2,376 (medical management)]. The overall intent-to-treat analysis showed no statistically significant difference in the incidence of allcause strokes, which included both cryptogenic and other strokes (p=0.16). When subsequent strokes wer Results from the RESPECT Trial Reported at TCT 2015 e restricted to cryptogenic stroke, there was a 54% relative risk reduction in recurrent cryptogenic stroke for the PFO closure group (p=0.042), although the absolute number of strokes remained small. An additional sensitivity analysis of all-cause stroke in patients under the age of 60 (where a greater proportion of strokes are likely to be cryptogenic) showed a 52% relative risk reduction (p=0.035). Additional benefit was also seen within a subgroup in 2/3 of RESPECT patients who had PFO characteristics of substantial shunt or atrial septal aneurysm with a 75% reduction in cryptogenic stroke risk (p=0.007). Results from the RESPECT Trial Reported at TCT

19 ΑΠΟΤΕΛΕΣΜΑΤΑ Analysis of PFO Closure procedure or device-related serious adverse events found no intra-procedure strokes, device embolization, device thrombosis or device erosion. There was a low rate of major vascular complications (0.9%) and device explants (0.4%). Results from the RESPECT Trial Reported at TCT 2015

20 PFO & MIGRAINE

21 ΑΛΛΕΣ ΕΝΔΕΙΞΕΙΣ Decompression Sickness Deep sea divers Platypnea-Orthodeoxia Systemic Embolization

22 ΣΥΣΚΕΥΕΣ ΣΥΓΚΛΕΙΣΗΣ Amplatzer PFO NMT Starflex Helix

23 AMPLATZER

24 HELIX

25

26 ΤΥΠΟΙ ΜΕΣΟΚΟΛΠΙΚΗΣ ΕΠΙΚΟΙΝΩΝΙΑΣ

27 ASD SECUNDUM

28 ASD. Secundum, Multiple

29 ASD. Sinus Venosus

30 ΕΝΔΕΙΞΕΙΣ

31 INDICATIONS FOR ASD CLOSURE FROM ACC/AHA(2013) Right atrial and right ventricular enlargement by echocardiography with or without symptoms. ASD minimum diameter should be > 5 mm and < 40 mm on echocardiography. Adequate rims of tissue (> 5 mm) from the defect to surrounding structures such as the coronary sinus,svc, IVC, and AV valves, as well as the pulmonary veins. Presence of an ASD with documented or verified paradoxical embolization and/or documented orthodeoxia-platypnea. Net left-to-right shunting, pulmonary artery pressures less than twothirds systemic levels, pulmonary vascular resistance less than twothirds systemic vascular resistance, when either is responsive to pulmonary vasodilators, or test occlusion of the defect is successful.

32 ΑΝΤΕΝΔΕΙΞΕΙΣ ΣΥΓΚΛΕΙΣΗΣ Aortic rim absence or severe deficiency confirmed in multiple TEE views. Absence of rims documented in multiple views of 30º, 40º, 50º+. IVC rim absence or severe deficiency. Pulmonary vascular resistance > 15 Woods units is an absolute contraindication. Patients with PVR between 10 and 15 should have aggressive antipulmonary hypertensive treatment for 6 months and evaluation before exploring ASD closure. Coronary sinus rim absence with evidence of coronary sinus impingement by the device in the catheterization laboratory. Mitral valve impingement by the device with evidence of new-onset or increasing mitral insufficiency. Try a smaller device, if feasible. Development of AV block after device deployment

33 ΑΟΡΤΙΚΟ ΧΕΙΛΟΣ-ΟΡΙΟ ΣΥΓΚΛΕΙΣΗΣ If 5 mm is considered to be an adequate rim size, then aortic rim deficiency will be common because more than 40% of patients with ASD have an aortic rim that is < 5 mm. Therefore, aortic rim deficiency is not a generalized contraindication to device closure. The aortic rim, however, is the most important rim when it comes to device-related complications such as erosion.

34 AORTIC RIM

35 ASD-AMPLATZER

36 ΤΕΧΝΙΚΗ ΣΥΓΚΛΕΙΣΗΣ Femoral venous access TTE/ICE imaging for PFO TEE, 3DTEE or ICE imaging for ASD IV heparin to ACT > 250 sec Catheter access across defect Balloon sizing of defect Exchange for delivery sheath Device deployment and release Confirmatory imaging- PAKMAN Sign Total time: ~30 minutes for PFO, ~60 minutes for ASD

37 ΤΕΧΝΙΚΗ ΣΥΓΚΛΕΙΣΗΣ

38

39 ΕΠΙΠΛΟΚΕΣ ΣΥΓΚΛΕΙΣΗΣ Stroke Cardiac tamponade from cardiac perforation Device-associated thrombus Device embolization Device erosion Incomplete defect closure

40